@article{e530003d44c045968d8f7451f5b20611,
title = "Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis",
abstract = "Background: Bowel ultrasonography is a non-invasive imaging tool that can repeatedly monitor ulcerative colitis (UC) activity. Aim: This study aimed to determine whether early transabdominal or transperineal ultrasonography changes can predict subsequent clinical response to induction therapy in patients with UC. Methods: This single-centre prospective study explored ultrasonographic predictors for clinical remission (patient-reported outcome-2 ≤ 1 with no rectal bleeding subscore) at week 8 in patients with active UC who underwent induction therapy, in comparison with faecal calprotectin and C-reactive protein (measured at baseline, week 1 and week 8). Predictive factors were assessed using multivariable regression models and receiver-operating-characteristic curve analysis. Results: A total of 100 patients were analysed, of which 54 achieved remission at week 8. Baseline biomarker and ultrasonographic-parameter values were not predictive of remission. Contrastingly, change from baseline to week 1 in rectal bowel wall thickness measured using transperineal ultrasonography was an independent predictor of remission by week 8 (adjusted odds ratio is associated with a 1-mm decrease: 1.90 [95% confidence interval, 1.22–2.95]). In a subgroup analysis of the patients who did not achieve remission in 1 week, the predictive value of change in rectal bowel wall thickness remained high (AUC = 0.77 [95% confidence interval, 0.61–0.88]). Conclusion: Improvement in rectal bowel wall thickness measured using transperineal ultrasonography at week 1 predicts treatment success and potentially facilitates decision making during the early course of induction therapy in UC.",
keywords = "gastrointestinal ultrasonography, induction treatment, inflammatory bowel disease, prognosis",
author = "Shintaro Sagami and Taku Kobayashi and Kanako Aihara and Misaki Umeda and Kazuhiro Odajima and Hiromu Morikubo and Kunio Asonuma and Yusuke Miyatani and Tomohiro Fukuda and Mao Matsubayashi and Hiroki Kiyohara and Masaru Nakano and Toshifumi Hibi",
note = "Funding Information: : Shintaro Sagami served as a speaker for AbbVie, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku and Zeria Pharmaceutical and as an endowed chair for AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical and EA Pharma. Taku Kobayashi served as a speaker, a consultant and an advisory board member for AbbVie, Ajinomoto Pharma, Asahi Kasei Medical, Astellas, Alfresa Pharma, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda Pharmaceutical, Thermo Scientific and Zeria Pharmaceutical and received research funding from AbbVie, Alfresa Pharma, Asahi Kasei Medical, EA Pharma, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Sekisui Medical, Thermo Fisher Scientific and Zeria Pharmaceutical. Hiromu Morikubo received research funding from Japan Foundation for Applied Enzymology. Kunio Asonuma served as an endowed chair for AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical and EA Pharma. Yusuke Miyatani served as a speaker for AbbVie and as an endowed chair for AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical and EA Pharma. Tomohiro Fukuda received research funding from Mitsubishi Tanabe Pharma. Masaru Nakano served as a speaker/consultant at Covidien, Mochida Pharmaceutical, Takeda Pharmaceutical, Zeria Pharmaceutical, Kyorin Pharmaceutical and Nippon Kayaku and received research funding from Mitsubishi Tanabe Pharma and the Japanese Foundation for Research and Promotion of Endoscopy. Toshifumi Hibi served as a speaker, a consultant and an advisory board member for Aspen Japan K.K., JIMRO, AbbVie, Takeda Pharmaceutical, Zeria Pharmaceutical, Mitsubishi Tanabe Pharma, Kyorin Pharmaceutical, Ferring, Gilead Sciences, Janssen Pharmaceutical, Kissei Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Bristol‐Myers Squibb, Celltrion, EA Pharma, Eli Lilly and Nichi‐Iko Pharmaceutical and received research funding from AbbVie, JIMRO, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Takeda Pharmaceutical, Zeria Pharmaceutical, Kyorin Pharmaceutical and Otsuka Holdings. None of the funding received for this work was from any of the above organisations. The authors not listed have no conflicts of interest to declare. Declaration of personal interests Funding Information: Declaration of personal interests: Shintaro Sagami served as a speaker for AbbVie, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku and Zeria Pharmaceutical and as an endowed chair for AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical and EA Pharma. Taku Kobayashi served as a speaker, a consultant and an advisory board member for AbbVie, Ajinomoto Pharma, Asahi Kasei Medical, Astellas, Alfresa Pharma, Celltrion, Covidien, EA Pharma, Eisai, Eli Lilly, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical, JIMRO, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda Pharmaceutical, Thermo Scientific and Zeria Pharmaceutical and received research funding from AbbVie, Alfresa Pharma, Asahi Kasei Medical, EA Pharma, Kyorin Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Otsuka Holdings, Sekisui Medical, Thermo Fisher Scientific and Zeria Pharmaceutical. Hiromu Morikubo received research funding from Japan Foundation for Applied Enzymology. Kunio Asonuma served as an endowed chair for AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical and EA Pharma. Yusuke Miyatani served as a speaker for AbbVie and as an endowed chair for AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical and EA Pharma. Tomohiro Fukuda received research funding from Mitsubishi Tanabe Pharma. Masaru Nakano served as a speaker/consultant at Covidien, Mochida Pharmaceutical, Takeda Pharmaceutical, Zeria Pharmaceutical, Kyorin Pharmaceutical and Nippon Kayaku and received research funding from Mitsubishi Tanabe Pharma and the Japanese Foundation for Research and Promotion of Endoscopy. Toshifumi Hibi served as a speaker, a consultant and an advisory board member for Aspen Japan K.K., JIMRO, AbbVie, Takeda Pharmaceutical, Zeria Pharmaceutical, Mitsubishi Tanabe Pharma, Kyorin Pharmaceutical, Ferring, Gilead Sciences, Janssen Pharmaceutical, Kissei Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Bristol-Myers Squibb, Celltrion, EA Pharma, Eli Lilly and Nichi-Iko Pharmaceutical and received research funding from AbbVie, JIMRO, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Takeda Pharmaceutical, Zeria Pharmaceutical, Kyorin Pharmaceutical and Otsuka Holdings. None of the funding received for this work was from any of the above organisations. The authors not listed have no conflicts of interest to declare. Declaration of personal interests: None. Declaration of funding interests: This study was partially funded by Kitasato University Kitasato Institute Hospital, Tokyo, Japan (Grant no. 18015). The authors are grateful to Tadae Mori, Toyomi Ishibashi, Tetsuo Kanazawa, Noritaka Hayashi and Yuki Watanabe for assisting with this study. The authors also thank Satoshi Kuronuma and Osamu Takeuchi for measuring faecal calprotectin levels as well as Barrett G. Levesque for providing critical suggestions regarding the manuscript. The data underlying this article will be shared upon reasonable request to the corresponding author. Funding Information: This work was supported by Kitasato University Kitasato Institute Hospital, Tokyo, Japan (Grant no. 18015). Publisher Copyright: {\textcopyright} 2022 John Wiley & Sons Ltd.",
year = "2022",
month = may,
doi = "10.1111/apt.16817",
language = "English",
volume = "55",
pages = "1320--1329",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "10",
}